Contraline key facts
as of Oct 2026- Developer of a male contraceptive product intended to provide non-surgical and reversible birth control procedures.
- Contraline is valued at approximately $60.0M as of Oct 2026 (last reported valuation).
- It has raised $41.7M across 3 recorded rounds; the latest was Later Stage VC ($55.8M) in May 2026.
- Notable investors include Alumni Ventures, Kima Ventures, Gaingels, Metaplanet Holdings, GV — 52 tracked in total.
- 3 investment vehicles were formed to buy Contraline shares in the last 12 months, reporting $2.3M sold to 106 investors, per SEC Form D filings.
- Contraline has filed 1 Form D with the SEC, most recently Apr 2022 ($7.2M sold to 22 investors).
- Status: Privately Held (backing).
Contraline's last reported valuation, Feb 2025. Nothing priced has surfaced since.
- ·The complete investor list: 52 names
- ·Watch Contraline: the Monday email on marks, rounds and moves
Contraline funding rounds
3 roundsVehicles formed to buy Contraline shares
secondary demand · SEC Form D filingsIn the last 12 months, 3 investment vehicles were formed to buy Contraline shares, reporting $2.3M sold to 106 investors across 3 sponsors. Most recent filing Jun 2026.
Membership and data by Private Market View
Who backs Contraline
52+Membership and data by Private Market View
Contraline valuation
Contraline's last reported valuation was $60 million in Feb 2025. No priced round, secondary trade or fund mark has surfaced since.
How much has Contraline raised?
Contraline has raised $41.7 million across 3 recorded rounds since 2021. The largest was a $7.2 million later-stage round in Apr 2022; the most recent was a $55.8 million later-stage round in May 2026.
Contraline has filed 1 Form D with the SEC, most recently in Apr 2022 ($7.2 million sold to 22 investors).
Institutional holders and vehicles
In the last 12 months, 3 investment vehicles were formed to buy Contraline shares, reporting $2.3 million sold to 106 investors across 3 sponsors, per SEC Form D filings (most recent Jun 2026).
Contraline investors
52 investors are on record for Contraline, including Alumni Ventures, Kima Ventures, Gaingels and Metaplanet Holdings. By type, the record holds 14 venture capital firms and 1 angel investor. The later-stage round in May 2026 drew 77 investors.
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: Pangea Bio ($80 million), Parallel Bio ($71.5 million) and Hinge Bio ($46 million).
About Contraline
Developer of a male contraceptive product intended to provide non-surgical and reversible birth control procedures. The company's technology implants a non-hormonal, non-surgical, and reversible polymer hydrogel into the vas deferens for contraception and acts as a semi-permeable membrane, blocking sperm while allowing fluids through, enabling users to get a cost-effective approach to contraception easily.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Charlottesville, VA, United States
- Founded
- 2015
- Employees
- 23
- Website
- contraline.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.